Full Press Release Details
Sydney, 16 November 2022 Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company,
is pleased to provide the results of the Company s AGM, held earlier today.
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia.
Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer.
Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed phase II study in glioblastoma reported promising signals of efficacy in 2021, and a pivotal study for registration, GBM
AGILE, is ongoing, with final data expected in 2H CY2023. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data.
Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in
August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for atypical teratoid / rhabdoid tumours (AT/RT) in June 2022 and July 2022, respectively.
Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021.
This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director.
Kazia Therapeutics Limited
Annual General Meeting
Wednesday, 16 November 2022
information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.
| Resolution details | Instructions given to validly appointed proxies (as at proxy close) | Number of votes cast on the poll (where applicable) | Resolution Result | |||||||||||||||
| Resolution | Resolution Type | For | Against | Proxy s Discretion | Abstain | For | Against | Abstain* | Carried / Not Carried | |||||||||
| 1 Adoption of Remuneration Report | Ordinary | 18,737,349 61.03% | 11,787,139 38.39% | 177,839 0.58% | 27,022,451 | 19,252,815 62.03% | 11,787,139 37.97% | 27,022,451 | Carried | |||||||||
| 2 Re-Election of Steven Coffey | Ordinary | 52,294,495 89.24% | 6,126,952 10.46% | 178,439 0.30% | 2,099,020 | 52,804,989 89.60% | 6,126,952 10.40% | 2,104,592 | Carried | |||||||||
| 3 Approval of grant of Options to Dr James Garner | Ordinary | Resolution withdrawn | Resolution withdrawn | Not Applicable | ||||||||||||||
| 4 Ratification of prior issue of ATM Shares | Ordinary | 50,147,662 83.12% | 10,002,735 16.58% | 178,439 0.30% | 370,070 | 50,663,728 83.51% | 10,002,735 16.49% | 370,070 | Carried | |||||||||
| 5 Approval of Additional Placement Capacity under Listing Rule 7.1A | Special | 50,006,395 83.41% | 9,613,179 16.04% | 327,938 0.55% | 751,394 | 50,671,960 84.05% | 9,613,179 15.95% | 751,394 | Carried | |||||||||
| 6 Adoption of New Constitution | Special | 52,170,337 87.47% | 7,279,241 12.20% | 198,439 0.33% | 1,050,889 | 52,700,831 87.86% | 7,279,241 12.14% | 1,056,461 | Carried | |||||||||
| 7 Approval of Proportional Takeover Provisions | Special | 54,531,437 90.38% | 5,622,998 9.32% | 178,439 0.30% | 366,032 | 55,041,931 90.73% | 5,622,998 9.27% | 371,604 | Carried |
In relation to resolution 1 Adoption of Remuneration Report, as more than 25% of the votes were cast against this resolution, this
constitutes a first strike for the purposes of the Corporations Act 2001 (Cth).
Resolution(s) proposed but not put to the meeting
| Resolution | Reason(s) for not putting the resolution to the meeting | |
| 3 Approval of grant of Options to Dr James Garner | Resolution withdrawn prior to AGM |